Patients Discontinuing Slimming Injections Gain Back Weight Four Times Faster Compared to Dieters

New research reveals that individuals who stop using popular GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass far faster than those who stop conventional diet and exercise regimens.

Findings released in a major health publication demonstrates that while obese individuals frequently drop a large proportion of their total mass while on the medication, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.

"Individuals using these medications must be cognizant of the potential of quick rebound weight gain when the therapy is stopped," stated expert Dr. Susan Jebb.

This pace of regain means a return to starting weight within about one and a half years.

Weighing Approaches

The analysis, which looked at dozens of studies involving over 9,000 of participants, compared the outcomes of GLP-1 agonists with conventional dieting.

Scientists note that individuals who lose weight through dieting generally see a slower creep back—perhaps 0.1 kg a month—once they finish.

Explaining the Rapid Rebound

Nutrition scientists suggest the way of the drugs explains the heightened regain.

These medications copy a body's own chemical called GLP-1, which helps regulate appetite.

"Artificially providing the hormone concentrations several times higher than the body's typical production may cause the body to produce less of its endogenous GLP-1, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a dietetics expert.

"Discontinuation of this hormone supplement results in appetite is no longer kept in check, making excessive eating a significant risk."

An Ongoing Disease?

Health authorities advise the injections for individuals with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.

Professionals argue that, considering the high risk of relapse, the treatment should be considered ongoing.

This opinion is reinforced by pharmaceutical companies, who note that the findings "highlight the long-term character of obesity," akin to managing conditions like high blood pressure.

Patient Testimonies

Users who have stopped the jabs describe a powerful resurgence of appetite.

"It was like something flipping and you become ravenous," said a patient.

The struggle is exacerbated if patients have not established permanent lifestyle or habit changes during therapy.

Widespread Adoption

Figures indicate that millions of adults in the UK have used these injections in the last 12 months, with desire continuing to grow.

• Adoption is greater among females compared to males.
• The 40s and 50s demographic shows the highest level of interest.
• Many access the drugs through private prescriptions rather than public health services.

Ultimately, researchers emphasize that while the jabs are effective agents for shedding pounds, they are not a standalone solution and maintained weight loss hinges on integrated lifestyle changes.